HUTCHMED (China) - ADR Peer Comparison
$14.13
$0.19
(1.36%)
As on 28-Sep-2026 16:00EDT
Market cap
$2,423 Mln
Revenue (TTM)
$549 Mln
P/E Ratio
139.4
P/B Ratio
2
Div. Yield
0 %
Edit
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,423 | 2,804 | 1,963 | 727 | 695 |
Revenue ($ Mln) |
549 | 450 | 121 | -- | 1 |
Net Profit ($ Mln) |
17.88 | -188.21 | -57.76 | -175.85 | -59.95 |
Net Margin (%) |
3.26 | -41.86 | -47.82 | -- | -9,759.23 |
RoE (%) |
1.43 | -28.46 | -9.91 | -106.84 | -118.98 |
Price to Earnings |
139.40 | -- | -- | -- | -- |
Price-To-Book |
1.98 | 4.89 | 3.50 | 4.97 | 18.60 |
Income Statement ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
549.12 | 449.61 | 120.25 | 0.00 | 0.61 |
|
Cost of Revenue
|
548.01 | 195.71 | 19.21 | 12.78 | 0.30 |
|
Gross Profit
|
212.72 | 269.08 | 12.07 | -17.67 | 0.34 |
|
Operating Expenses
|
35.89 | 517.90 | 154.86 | 176.86 | 67.15 |
|
Operating Profit (EBIT)
|
-34.78 | -264.00 | -51.50 | -181.14 | -66.84 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
20.08 | -190.72 | -57.14 | -178.93 | -59.95 |
|
Provision for Tax
|
1.66 | -2.51 | 0.62 | -3.09 | 0.00 |
|
Profit after Tax (Net Income)
|
17.88 | -188.21 | -57.50 | -175.85 | -59.95 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,260.78 | 607.04 | 568.41 | 160.40 | 38.47 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
186.25 | 39.17 | 123.56 | 8.50 | 55.23 |
|
Current Liabilities
|
275.21 | 428.58 | 81.11 | 54.30 | 12.71 |
|
Total Liabilities
|
1,753.10 | 1,172.38 | 784.68 | 233.72 | 131.44 |
Assets ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
183.02 | 160.76 | 575.59 | 21.30 | 12.13 |
|
Current Assets
|
1,553.41 | 914.04 | 197.49 | 201.90 | 94.28 |
|
Total Assets
|
1,753.10 | 1,172.38 | 784.68 | 233.72 | 131.44 |
|
Total Debt*
|
94.51 | 254.58 | 127.33 | 21.00 | 0.11 |
|
Net Current Assets
|
0.00 | 485.45 | 116.38 | 147.60 | 81.57 |
Cashflow ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-64.66 | -150.79 | -49.95 | -121.18 | -62.27 |
|
Cash Flow from Investing Activities
|
-29.41 | 307.87 | 0.12 | -1.37 | -47.99 |
|
Cash from Financing Activities
|
7.84 | 72.35 | 147.34 | 276.18 | 0.02 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
41.92 | -18.15 | -15.42 | -130.25 | -104.49 |
|
ROE (%)
|
1.43 | -28.46 | -10.06 | -106.84 | -118.98 |
|
ROA (%)
|
0.66 | -12.55 | -6.60 | -74.77 | -40.08 |
|
EBIT Margin (%)
|
-6.33 | -41.09 | -42.62 | -- | -9,892.63 |
|
Net Margin (%)
|
3.26 | -41.86 | -47.82 | -- | -9,759.23 |
|
Cash Profit Margin (%)
|
-- | 0.00 | -- | -- | -0.02 |
Growth Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-8.81 | 5.10 | 599.21 | -1.00 | -97.63 |
|
EBIT Growth (%)
|
-76.55 | 11.36 | 17.93 | -45.21 | 26.29 |
|
Net Profit Growth (%)
|
-96.17 | 11.44 | 43.71 | -43.04 | 31.30 |
|
EPS Growth (%)
|
-96.17 | -1.87 | 47.43 | 7.30 | 31.24 |
|
Book Value Growth (%)
|
2.54 | -25.05 | -6.65 | 108.85 | -59.14 |
Valuation Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
5.08 | -11.11 | -13.58 | -9.99 | -1.08 |
|
Price / Book Value
|
1.88 | 2.73 | 2.32 | 8.70 | 1.54 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-25.58 | -9.39 | -18.38 | -9.30 | -0.12 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.19 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.02 | 0.40 | 0.02 | 0.09 | 0.00 |
|
Current Ratio
|
5.64 | 2.13 | 2.43 | 3.72 | 7.42 |
|
Quick Ratio
|
5.50 | 1.92 | 2.09 | 3.72 | 7.42 |
|
Interest Coverage
|
-19.05 | -30.87 | -4.06 | -- | -- |
Operating Efficiency Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Silence Therapeutics PLC (SLN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
21.41 | 16.23 | 47.46 | -- | 1,512.64 |
|
Asset Turnover
|
0.20 | 0.30 | 0.14 | 0.00 | 0.00 |
|
Receivable days
|
104.79 | 77.60 | 380.35 | -- | 8,295.02 |
|
Inventory Days
|
49.57 | 109.55 | 791.94 | -- | -- |
|
Payable days
|
47.68 | 231.78 | 931.00 | 650.68 | 6,253.37 |
|
Cash Conversion Cycle
|
106.67 | -44.63 | 241.30 | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
